HC Wainwright Expects Weaker Earnings for Tango Therapeutics

Tango Therapeutics, Inc. (NASDAQ:TNGX) – HC Wainwright decreased their Q1 2025 EPS estimates for Tango Therapeutics in a report issued on Monday, April 14th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.35) for the quarter, down from their prior forecast of ($0.34). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for Tango Therapeutics’ Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.52) EPS and FY2026 earnings at ($1.54) EPS.

Tango Therapeutics Trading Down 6.9 %

Shares of NASDAQ TNGX opened at $1.28 on Wednesday. The stock has a fifty day moving average price of $1.84 and a 200 day moving average price of $3.37. Tango Therapeutics has a 12-month low of $1.11 and a 12-month high of $12.02. The company has a market cap of $138.38 million, a P/E ratio of -1.08 and a beta of 1.03.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The firm had revenue of $4.12 million during the quarter, compared to analyst estimates of $7.84 million.

Institutional Investors Weigh In On Tango Therapeutics

Institutional investors have recently made changes to their positions in the company. State Street Corp raised its stake in Tango Therapeutics by 26.8% during the third quarter. State Street Corp now owns 2,318,208 shares of the company’s stock worth $17,850,000 after acquiring an additional 489,949 shares during the period. Geode Capital Management LLC grew its position in shares of Tango Therapeutics by 11.6% during the third quarter. Geode Capital Management LLC now owns 1,368,262 shares of the company’s stock worth $10,538,000 after acquiring an additional 142,710 shares during the last quarter. Schroder Investment Management Group bought a new stake in Tango Therapeutics in the 4th quarter valued at about $2,031,000. Swiss National Bank boosted its stake in Tango Therapeutics by 13.1% during the 4th quarter. Swiss National Bank now owns 94,900 shares of the company’s stock valued at $293,000 after purchasing an additional 11,000 shares during the period. Finally, American Century Companies Inc. grew its position in Tango Therapeutics by 12.4% in the 4th quarter. American Century Companies Inc. now owns 110,448 shares of the company’s stock worth $341,000 after purchasing an additional 12,162 shares during the last quarter. 78.99% of the stock is currently owned by institutional investors.

Insider Activity

In other Tango Therapeutics news, CEO Barbara Weber sold 9,778 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $2.99, for a total value of $29,236.22. Following the transaction, the chief executive officer now directly owns 1,631,264 shares of the company’s stock, valued at $4,877,479.36. This represents a 0.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last three months, insiders sold 24,268 shares of company stock worth $72,561. 6.30% of the stock is currently owned by company insiders.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.